Background. The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Methods. This was a 6-month, open-label, prospective and multicentre study. A total of 422 patients with type 2 diabetes who were hypertensive wsitting systolic blood pressure (SBP) P140 mmHg anduor diastolic blood pressure (DBP) P90 mmHgx and microalbuminuric wurinary albumin excretion (UAE) 30±300 mgudayx were eligible for the study. After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (-140u90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of control of BP, losartan 50 mgudayqhydroclorothiazide 12.5 mguday was administrated. Initially and at 12 and 24 weeks of active treatment, BP, UAE, HbA 1c and other renal function parameters were evaluated. Results. A signi®cant decrease in SBP and DBP was observed, as well as in parameters re¯ecting metabolic control, fasting glucose and HbA 1c . UAE also decreased signi®cantly, but the percentage of the variance of change in UAE explained by the changes in SBP and HbA 1c was, however, negligible, i.e. 4%. Moreover, small but signi®cant reductions in uric acid, total cholesterol and triglycerides, and an increase in HDL-cholesterol levels were also observed. Conclusion. Antihypertensive treatment with losartan exerts a bene®cial effect on UAE, a benchmark for measuring the ef®cacy of therapeutic interventions in diabetic nephropathy, by reducing BP and allowing better diabetes control. The role of other mechanisms in¯uencing the favourable outcome, beyond these measured effects, needs to be assessed in further studies.
Introduction
Because of the ageing of the population, an increasing prevalence of obesity and sedentary life habits, the prevalence of type 2 diabetes is increasing w1x. This type of diabetes is associated with a marked increase in the risk of cardiovascular disease. Hypertension, frequently found in patients with diabetes with a prevalence approximately twice that of the non-diabetic population w2x, further increases the already high risk of cardiovascular disease associated with type 2 diabetes w2±4x.
By the time patients are diagnosed with type 2 diabetes, many have already developed hypertension, microalbuminuria or even macroalbuminuria, and cardiovascular disease w3,5,6x. Microalbuminuria, that is present in a quarter of the patients at the time of diagnosis, is a strong predictor of all-cause mortality and of cardiovascular morbidity and mortality. Although the mechanism underlying the association between microalbuminuria and mortality is not clear, the presence of microalbuminuria may re¯ect a generalized defect in vascular permeability leading to atherogenesis w7x. Hypertension is a major risk factor for the development of microalbuminuria w8x.
The main goal of any treatment for patients with type 2 diabetic nephropathy should be to prevent the natural progression from microalbuminuria to macroalbuminuria and to end-stage renal disease, and to reduce cardiovascular morbidity and mortality. Effective antihypertensive treatment is the best inhibitor of diabetic nephropathy w9x. Since reducing albuminuria delays progression of diabetic nephropathy, this parameter can be used as a benchmark for measuring the ef®cacy of therapeutic interventions w10x. Angiotensin II has been implicated in the progression of renal failure in diabetic nephropathy w11x. Blockade of the renin±angiotensin system (RAS) with angiotensinconverting enzyme inhibitors (ACEIs) w12,13x may reduce albumin excretion more than other agents in patients with type 2 diabetic nephropathy, but their effect on the glomerular ®ltration rate (GFR) may be similar w14x. Losartan, an antagonist of the AT 1 angiotensin II receptor (ARAII), has been shown to induce changes in renal haemodynamics and proteinuria similar to those induced by the ACEI enalapril, indicating that the antiproteinuric effect of ACE inhibition is mediated primarily by RAS blockade w15,16x.
The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Furthermore, the relationship between changes in the blood pressure and changes in the urinary albumin excretion (UAE) were analysed.
Patients and methods
This was a 6-month, open-label, prospective and multicentre study. Patients with type 2 diabetes who were hypertensive wsitting systolic blood pressure (SBP) P140 mmHg anduor diastolic blood pressure (DBP) P90 mmHgx and microalbuminuric (UAE 30±300 mguday) were eligible for the study. Exclusion criteria were: (i) patients with secondary hypertension; (ii) those without pharmacological treatment or receiving a combination of two or more antihypertensive drugs; (iii) those with congestive heart failure (NYHA class III or IV); (iv) serum creatinine )2 mgudl; and (v) known hypersensitivity or intolerance to losartan.
After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (-140u90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of control with losartan 100 mguday, losartan 50 mgudayqhydroclorothiazide 12.5 mguday was administrated to achieve the desired BP. Interview and physical examination assessed side effects, concomitant diseases and blood pressure at each visit during the treatment. All patients were counselled to follow a low sodium and balanced carbohydrate diet, and investigators were instructed to maintain, if possible, the same antidiabetic therapy throughout the complete study.
Blood pressure was measured using a mercury sphygmomanometer with the patient in the sitting position after 5 min of rest in a quiet environment, following the recommendations of the British Hypertension Society w17x. SBP and DBP (Korotkoff phase I and phase V, respectively) were the mean of three readings measured at 10-min intervals.
Initially, UAE was assessed using a semiquantitative method (Micral-test, Boehringer Mannheim) on three ®rst-morning urine samples. If at least two were positive (P50 mguml), a 24-h urine collection was obtained and UAE was measured using an immunonephelometric assay (Behring Institute). Aliquots of urine were taken from the 24-h sample in glass tubes at 48C and were analysed 1±7 days after collection.
Microalbuminuria, glycosylated haemoglobin, serum lipids, routine haematological and blood chemistry analyses (haematological indices, blood glucose, serum sodium and potassium concentrations, liver enzyme levels, uric acid, urea and creatinine concentrations) were done at baseline, and at 12 and 24 weeks of active treatment.
For each variable, the values were expressed as mean"SD. The UAE data were analysed as a continuous variable with logarithmic transformation. Assessment of changes in variables over time was performed by paired t-test. Pearson correlation coef®cients were used to examine the linear relationship between the changes in logUAE and the changes in BP or glycosylated haemoglobin. The independent association between these variables and logUAE was examined by multivariate regression analysis. P-values -0.05 were considered signi®cant.
The drug treatment was well tolerated, and secondary effects that result in drug withdrawal were observed in only 1.2% of the subjects.
Results
From a total of 445 patients recruited, 424 were suitable for the analysis. The general characteristics of the study population are summarized in Table 1 . Twenty-two percent of the patients were diagnosed recently and had not received previous antihypertensive therapy, 25% were treated with an ACEI, 24% with calcium channel blockers, 15% with diuretics, 9% with b-blockers, and 5% with other drug classes. During the treatment period, SBP control was achieved in 70% of the patients, 23% of them after the addition of hydrochlorothiazide. Diastolic BP was controlled in 82% of the patients, 20% after the addition of the diuretic.
The impact of treatment on body weight, BP values, HbA 1c , UAE and other parameters is shown in Table 1 . A signi®cant decrease in SBP and DBP was observed, as well as in parameters re¯ecting metabolic control, fasting glucose and HbA 1c . This improvement in BP and metabolic control was followed by a signi®cant reduction in UAE (from 115"85 mgu24 h to 66"55 mgu24 h, P-0.0001). One hundred and seven patients (25%) normalized their microalbuminuria. Moreover, small but signi®cant reductions in uric acid, total cholesterol and triglycerides, and an increase in HDL-cholesterol levels were also observed.
The change in UAE over time was weakly, although signi®cantly, correlated with the changes in SBP (Figure 1 ). When a multiple regression analysis was performed using as a dependent variable the change in logUAE, the changes in SBP and HbA 1c were independently signi®cant parameters. The percentage of the variance of change in UAE explained by the changes in SBP and HbA 1c was, however, negligible, at 4%.
Discussion
In a large group of hypertensive, microalbuminuric, type 2 diabetics, losartan reduced BP values and UAE during a 6-month period of treatment. The administration of losartan permits a signi®cant improvement in metabolic parameters, mainly those re¯ecting carbohydrate (baseline glucose, HbA 1c ) and lipid (triglycerides, HDL-cholesterol) metabolism. A small but signi®cant reduction is also observed in uric acid levels. The main factor in¯uencing the observed reduction in UAE during the losartan treatment might be BP reduction. Clinical trials have demonstrated the effect of various antihypertensive agents on proteinuria in patients with diabetes. In a meta-analysis of 100 controlled and uncontrolled trials, the relative effect of different antihypertensive agents on proteinuria was assessed w12x. Although treatments with ACEIs, calcium antagonists and b-blockers has a similar effect on mean arterial BP, the greatest reduction in UAE occurred in patients treated with ACEIs. A second meta-analysis, however, challenged the hypothesis and suggested that at maximal antihypertensive doses there was no signi®cant difference between the antiproteinuric effects of ACEIs and those of other antihypertensive drugs w18x. Thus, whether the effects of ACEIs on renal function in patients with diabetes are unique to this class of agent or represent a non-speci®c effect of BP reduction remains controversial.
Losartan, whose antihypertensive activity is due to the selective antagonism of angiotensin II at the AT 1 receptor, has been shown to induce changes in renal haemodynamics and proteinuria similar to those induced by the ACEI enalapril, indicating that the antiproteinuric effect of ACE inhibition is mediated primarily by RAS blockade w15,16x. In the present study, the weak correlation observed between changes in logUAE and changes in BP values indicated that other factors may be involved in UAE reduction.
Among those factors, the improvement of diabetes control should be mentioned. Adequate metabolic control is a key point in the treatment of diabetic patients. The impact of HbA 1c reduction on UAE has been demonstrated in the UKPDS w19x, and in the present study a signi®cant change was observed during antihypertensive treatment with losartan. A neutral or positive effect of losartan on insulin resistance has been found, allowing a better diabetes control.
Finally, the bene®cial effect of speci®c RAS blockade, other than BP and HbA 1c reduction, needs to be considered. Angiotensin II has been implicated in the progression of renal failure in diabetic nephropathy w11x, up-regulating the expression of growth factors and cytokines such as transforming growth factor-b1, tumour necrosis factor-a, osteopontin, vascular cell adhesion molecule 1, nuclear factor-kB, plateletderived growth factor, ®broblast growth factor and insulin-like growth factor w20,21x. Losartan reduces the increased levels of some of these growth factors and cytokines w20x.
In summary, antihypertensive treatment with losartan exerts a bene®cial effect on UAE, a benchmark for measuring the ef®cacy of therapeutic intervention in diabetic nephropathy, by reducing BP and allowing better diabetes control. The role of other mechanisms in¯uencing the favourable outcome, beyond these measured effects, needs to be assessed in further studies. 
